Physician profile
Jason E Goodman
NPI 1447275110
$3,226.44
in general payments reported to CMS, 2019-2025
21 companies · $964 in 2025
The $964 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $409 · 2023: $1,046 · 2024: $807 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,817.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $787.20 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $478.24 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $470.97 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $199.73 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Silk Road Medical, INC. | $178.18 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Abbott Laboratories | $166.73 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $119.14 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $117.98 | 2022-2024 | |
| Glaxosmithkline, LLC. | $114.87 | 2023-2025 | Trelegy Ellipta |
| Amgen INC. | $105.01 | 2023-2025 | Repatha, Otezla, Uplizna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.46 | 2025 | Jardiance |
| Dexcom, INC. | $89.75 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $72.36 | 2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $50.80 | 2022 | |
| Phadia US INC. | $43.80 | 2023-2025 | Immunocap |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $36.62 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $25.76 | 2025 | Voquezna |
| Watermark Medical, INC. | $19.92 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.28 | 2025 | Xifaxan |
| Medtronic, INC. | $18.69 | 2023 | Intellis Adaptivestim |
| Kowa Pharmaceuticals America, INC. | $15.95 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.